Stephen Gordon Sells 10,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDXGet Rating) CFO Stephen Gordon sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $56.72, for a total value of $567,200.00. Following the completion of the transaction, the chief financial officer now directly owns 5,714 shares of the company’s stock, valued at approximately $324,098.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Stephen Gordon also recently made the following trade(s):

  • On Monday, October 3rd, Stephen Gordon sold 10,000 shares of TransMedics Group stock. The stock was sold at an average price of $41.74, for a total value of $417,400.00.

TransMedics Group Price Performance

Shares of TMDX opened at $56.21 on Friday. The stock has a 50-day moving average of $47.01 and a 200-day moving average of $38.47. TransMedics Group, Inc. has a one year low of $10.00 and a one year high of $60.51. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.41 and a current ratio of 12.11.

TransMedics Group (NASDAQ:TMDXGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.15. TransMedics Group had a negative return on equity of 46.03% and a negative net margin of 58.78%. The firm had revenue of $25.68 million during the quarter, compared to analysts’ expectations of $18.96 million. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post -1.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new position in TransMedics Group in the 2nd quarter valued at about $31,000. MCF Advisors LLC purchased a new stake in TransMedics Group during the 3rd quarter worth about $43,000. Prospera Financial Services Inc purchased a new position in TransMedics Group during the 2nd quarter valued at about $69,000. Tower Research Capital LLC TRC increased its position in shares of TransMedics Group by 125.4% during the third quarter. Tower Research Capital LLC TRC now owns 2,603 shares of the company’s stock valued at $109,000 after buying an additional 1,448 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of TransMedics Group in the third quarter worth about $148,000. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on TMDX shares. Canaccord Genuity Group lifted their price objective on TransMedics Group from $58.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, November 4th. Cowen increased their price objective on shares of TransMedics Group from $39.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 26th. Oppenheimer upped their price target on shares of TransMedics Group from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, August 2nd. Morgan Stanley lifted their price objective on TransMedics Group from $45.00 to $54.00 and gave the stock an “equal weight” rating in a research report on Friday, November 4th. Finally, JPMorgan Chase & Co. upgraded TransMedics Group from a “neutral” rating to an “overweight” rating and upped their target price for the company from $26.00 to $48.00 in a research report on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.14.

TransMedics Group Company Profile

(Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Stories

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.